NCT07778173

Recruiting

Three-Dimensional Molds Based on Radiological imagEs in Pati...

Tampere University Hospital Source

Compare

Other study identifiers

Sponsor study identifier

R23084

Study Type

interventional

Estimated enrollment

30

Locations

1 country

Sites

1

Timeline

Study Start

May 31, 2024

Actual (reported)

Primary Completion

December 2033

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

December 15, 2033

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Estimated enrollment: 30 participants
Study completion date: December 15, 2033
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
May 31, 2024
Actual (reported)
First Submitted
August 10, 2026
Actual (reported)
First Posted
August 21, 2026
Actual (reported)
Primary Completion
December 2033
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 15, 2033
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: August 21, 2026
Status Verified: August 2026
Last Update Submitted: August 20, 2026

Conditions

Cancer Tumor

Outcome Measures

Primary Outcomes (1)

2. Histopathological evaluation
Rate of malignant/benign and higher/lower grade tumor tissue in the samples obtained using 3D-molds
After the surgery upon review of the histopathological sample (within 3 months of the operation)

Secondary Outcomes (1)

Biomarker evaluation from the samples obtained using 3D-mold
After the surgery throughout the study period and upon the completion of study recruitment within 3 months

Study Arms (1)

Study arm

EXPERIMENTAL

Procedure: 3D-printed tumor mold for tissue sampling

Interventions

3D-printed tumor mold for tissue samplingProcedure

3D-printed tumor mold for tissue sampling

Study arm

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

To be eligible for the study, the study candidate must:
be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (\<15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s))

Sponsors & Collaborators

Kuopio University Hospital
Othercollaborator
Tampere University Hospital
Otherlead
Tampere University

Study Sites (1)

Tampere University Hospital

Tampere, Finland

RECRUITING

Otso Arponen, MDCONTACT+358 3 311 611 otso.arponen@tuni.fi

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Otso Arponen, MD

CONTACT

+359 3 311 611 otso.arponen@tuni.fi

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: DIAGNOSTIC
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 10, 2026

First Posted

August 21, 2026

Study Start

May 31, 2024

Actual (reported)

Primary Completion

December 2033

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

NCT01269645

Facts and Attitudes About Clinical Trials

Not ApplicableCompleted

NCT03942614

Nordic Pole Walking for Individuals With Cancer

Not ApplicableCompleted

NCT03945734

Expressive Helping for Chinese-Speaking Cancer Patients and Survivors

Not ApplicableCompleted

NCT06186427

A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors

Not ApplicableUnknown

NCT05887401

Physical Activity and Healthy Eating Among Young Adult Cancer Survivors

Not ApplicableCompleted

NCT07356726

Finding My Way-UK: Promoting Positive Psychological Outcomes in People Living With and Beyond Curatively Treated Cancer

Not ApplicableNot Yet Recruiting

have a malignant or likely malignant tumor/tumors and undergo a surgical operation.

You may not qualify if:

To be eligible for the study, the study candidate cannot:
lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (\<15-year-old), the child is not eligible);
be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.

Contact the study team to confirm eligibility.

Othercollaborator

University of Eastern Finland

Othercollaborator

Study Completion

December 15, 2033

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

August 21, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07778173
Data provider: ClinicalTrials.gov
Source updated: 2026-08-21
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:04 UTC

Locations

FI(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Study arm

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations